Condition: Bipolar Disorder I or II With a Major Depressive Episode · Sponsor: Alto Neuroscience
The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used adjunctively to a mood stabilizer and/or atypical antipsychotic, related to patient characteristics. Additionally, safety, tolerability, and efficacy will be assessed in a subsequent open label treatment period.
This description comes directly from the study's public registry record.
Alto Neuroscience · 650-200-0412 · clinical@altoneuroscience.com
Always discuss trial participation with your own doctor first.
| Site 6036 | Chandler, Arizona, United States | Withdrawn |
| Site 6000 | Phoenix, Arizona, United States | Recruiting |
| Site 6087 | Yuma, Arizona, United States | Recruiting |
| 6039 | Fayetteville, Arkansas, United States | Recruiting |
| 6070 | Little Rock, Arkansas, United States | Recruiting |
| Site 6081 | Imperial, California, United States | Recruiting |
| 6069 | Los Angeles, California, United States | Recruiting |
| Site 6016 | Mather, California, United States | Not Yet Recruiting |
| Site 6082 | Oceanside, California, United States | Recruiting |
| Site 6102 | Riverside, California, United States | Recruiting |
| Site 6112 | Colorado Springs, Colorado, United States | Not Yet Recruiting |
| Site 6067 | Lauderhill, Florida, United States | Withdrawn |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06656416